Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

73 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Early lesion detection with 18F-DCFPyL PET/CT in 248 patients with biochemically recurrent prostate cancer.
Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, Hoekstra OS, van Moorselaar RJA, Oprea-Lager DE, Vis AN. Wondergem M, et al. Among authors: knol rjj. Eur J Nucl Med Mol Imaging. 2019 Aug;46(9):1911-1918. doi: 10.1007/s00259-019-04385-6. Epub 2019 Jun 22. Eur J Nucl Med Mol Imaging. 2019. PMID: 31230088 Free PMC article.
18F-DCFPyL PET/CT for primary staging in 160 high-risk prostate cancer patients; metastasis detection rate, influence on clinical management and preliminary results of treatment efficacy.
Wondergem M, van der Zant FM, Broos WAM, Roeleveld TA, Donker R, Ten Oever D, Geenen RWF, Knol RJJ. Wondergem M, et al. Among authors: knol rjj. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):521-531. doi: 10.1007/s00259-020-04782-2. Epub 2020 Jul 27. Eur J Nucl Med Mol Imaging. 2021. PMID: 32719916
Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences.
van Altena EJE, Jansen BHE, Korbee ML, Knol RJJ, Luining WI, Nieuwenhuijzen JA, Oprea-Lager DE, van der Pas SL, van der Voort van Zyp JRN, van der Zant FM, van Leeuwen PJ, Wondergem M, Vis AN. van Altena EJE, et al. Among authors: knol rjj. Eur Urol Oncol. 2024 Oct 15:S2588-9311(24)00224-4. doi: 10.1016/j.euo.2024.09.015. Online ahead of print. Eur Urol Oncol. 2024. PMID: 39414419 Free article.
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification.
Hagens MJ, Luining WI, Boevé LMS, Knol RJJ, Roeleveld TA, Srbljin S, Weltings S, Koppes JCC, Oprea-Lager DE, Vis AN, van Leeuwen PJ, van der Poel HG. Hagens MJ, et al. Among authors: knol rjj. Prostate Cancer Prostatic Dis. 2024 Sep 23. doi: 10.1038/s41391-024-00899-9. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39313655
73 results